Teva to test glatiramer acetate in phase 3 trial

By Elaine Rigoli

Tampa, Fla., July 27 - Teva Pharmaceutical Industries said it started a phase 3 study to confirm the positive results from the phase 2 study that compared a 40 mg/day dose of glatiramer acetate (GA) to the currently approved Copaxone (GA) 20 mg/day.

The study will enroll about 1,000 patients in 160 centers across North America, Europe, Argentina and Israel, the company said in a news release

The results of the nine-month, randomized, double-blind, parallel-group phase 2 study suggested that patients taking the higher dose of GA had a 38% greater reduction in mean cumulative number of gadolinium-enhancing lesions as measured by brain MRI compared with those taking the Copaxone (GA) 20 mg/day dose.

Teva, based in Jerusalem, Israel, is a pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.